item management s discussion and analysis of financial condition and results of operations 
overview the company has devoted substantially all of its resources to the research and development of its proprietary technologies primarily the origen technology for clinical diagnostic and life science research products 
in february  the company completed an initial public offering of  shares of common stock from which it received net proceeds of approximately million 
in addition to product sales  the company s sources of revenue have consisted primarily of license or research payments pursuant to licensing or collaborative research agreements 
the company has entered into collaborative arrangements with corporate collaborators that provide for the development and marketing of certain origen systems 
these agreements provide fees and royalties payable to the company in exchange for licenses to produce and sell the resulting products 
in the near term  the company may selectively pursue additional strategic alliances although  over time  it expects an increasing amount of its revenues to be derived from sales of its products and royalties from corporate collaborations 
results of operations years ended march  and the company had revenues of million for the year ended march   compared to revenues of million for the corresponding period in fiscal revenue reflects a change in the revenue mix as compared to prior years 
during  a significant portion of the company s license and contract fees have converted to royalty income based on product sales of corporate partners 
fees from licenses and for contract research declined by million in fiscal to million and revenue from product sales and royalties increased to million in fiscal from million in the prior year 
this transition occurred primarily in the fourth quarter of fiscal as license and contract revenue declined by million while product sales and royalty income increased by  when compared to the increase in royalty income is directly attributable to royalties generated through the company s license agreement with boehringer mannheim gmbh 
boehringer mannheim recently launched its elecsys series of immunodiagnostic products which are based on the company s origen registered trademark technology 
through march   boehringer mannheim had more than  customer installations of its elecsys systems 
product costs were million in the year ended march  of product sales and million for the corresponding period in of product sales representing a change in the product mix between instruments  services and reagents 
research and development costs decreased to million for the year ended march  from million during this decrease is attributable to expiring external collaborations during marketing  general and administrative expenses increased million to million for the year ended march  when compared with the same prior year period 
this increase resulted primarily from increased marketing efforts associated with the origen detection system and administrative costs associated with the company s re incorporation in the state of delaware 
interest income net decreased to  in the year ended march  from million in the corresponding period in the decrease reflects the lower level of interest income derived from lower cash balances during the period as well as accrued interest expense attributable under an advance royalty agreement with boehringer mannheim 
see liquidity and capital resources following 
income loss from continuing operations over the next several years is likely to fluctuate substantially from quarter to quarter as a result of differences in the timing of revenues earned under license and product development agreements  and associated product development expenses 
as of march   the company had net operating loss and general business credit tax carryforwards of approximately million and million  respectively 
the company s ability to utilize its net operating loss and general business credit tax carryforwards may be subject to an annual limitation in future periods pursuant to the change in ownership rules under section of the internal revenue service code of  as amended 
years ended march  and the company had revenues of million for the year ended march   compared to revenues of million for the corresponding period in the increase in revenue is attributable to higher product sales which offset a decrease in revenue from contract research 
product sales from the company s origen detection system and related reagents and cell culture products increased to million in from million in  reflecting higher direct sales of the origen systems 
revenue from contract research decreased to million in from million in due to the level of research performed under a joint development contract with organon teknika 
product costs were million in the year ended march  of product sales and million in the corresponding period in of product sales 
the decreased percentage of product costs in reflected a change in the product sales mix between instruments and reagents 
research and development expenses increased to million in from million in this increase resulted from higher staffing levels  facilities costs associated with the company s relocation to a new building  and expanded external technical collaborations 
interest income net decreased to million in the year ended march   from million for the corresponding period in the decrease reflects a lower amount of interest derived from lower cash balances during the period 
liquidity and capital resources the company has financed its operations through placements of preferred and common stock  aggregating approximately million through march   including million in net proceeds received from the company s initial public offering which was completed during february in addition  the company has received funds from collaborative research and licensing agreements  and sales of its origen line of products 
as of march   the company had million in cash and cash equivalents 
working capital  excluding current deferred revenue which is classified as a current liability  was million at march  including current deferred revenue  working capital was million 
net cash used for operating activities was and million during the years ended march  and  respectively 
license and collaboration agreements between the company and its strategic corporate collaborators boehringer mannheim  organon teknika  eisai and perkin elmer provided payments to the company of million  of which million has been received through march  additionally  the company received million in january under an advance royalty agreement with boehringer mannheim 
the company used approximately  million and million of net cash for investing activities substantially related to the acquisition of laboratory equipment  furniture and leasehold improvements during the years ended march    and  respectively 
additionally  during fiscal years  and  the company incurred capital lease obligations of approximately   and  respectively  related to acquisition of laboratory equipment  furniture and leasehold improvements 
through march   the company  cumulatively  used approximately million to repurchase shares of its stock under a stock repurchase plan which was established in fiscal no repurchases were made during fiscal the company expects to incur substantial research and development expenses  manufacturing costs and marketing and distribution expenses in the future 
it is the company s intention to selectively seek additional collaborative or license agreements with suitable corporate collaborators  although there can be no assurance the company will be able to enter into such agreements or that amounts received under such agreements will reduce substantially the company s funding requirements 
additional equity or debt financing may be required  and there can be no assurance that these funds may be available on favorable terms  if at all 
the company s future capital requirements depend on many factors  including continued scientific progress in its diagnostics programs  the magnitude of these programs  the time and costs involved in obtaining regulatory approvals  the costs involved in filing  prosecuting and enforcing patent claims  competing technological and market developments  changes in its existing license and other agreements  the ability of the company to establish development arrangements  the cost of manufacturing scale up and effective commercialization activities and arrangements 

